Penicillin De-labeling in the Pediatric Primary Care Setting
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
While reported adverse reactions to penicillins are common, most patients with a penicillin
allergy label can safely tolerate penicillins, and elective evaluation for penicillin allergy
has been recommended. For low-risk patients, direct oral challenge may be an optimal approach
as a delabeling strategy. However, there is a vast disparity between the number of patients
with a penicillin allergy label and practicing allergists in the United States, and
implementing outpatient primary care-based delabeling strategies in low-risk patients may
increase access to delabeling assessments. However, a recent survey of pediatricians
identified perceived barriers to implementing penicillin allergy evaluations into their
routine care. Significant gaps in knowledge exist regarding the feasibility of this approach
involving risk stratification evaluation of reported penicillin adverse reactions and direct
amoxicillin challenge procedures in low-risk patients in the pediatric primary care setting.
With this, the primary aim of this study is to evaluate the number of patients for which
risk-stratification and direct amoxicillin challenge are successfully completed in an
outpatient pediatric primary care clinic.
Phase:
Phase 4
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
American College of Allergy, Asthma and Immunology